Frazier Life Sciences, a Palo Alto, CA-based venture capital firm investing in innovative biopharmaceuticals, added Lin Mu, M.D., MBA as a senior associate based in the Palo Alto office.
Mu’s multidisciplinary experience spans clinical research, therapeutic commercialization, and corporate strategy.
Prior to joining Frazier, Mu was a management consultant with Boston Consulting Group’s healthcare practice, where he advised biopharmaceutical clients on development and commercialization strategies. Previously, he was a clinical researcher at Beth Israel Deaconess Medical Center, where he supported clinical trial operations across therapeutic areas.
Frazier Life Sciences invests globally in private and publicly traded companies that discover, develop and commercialize innovative biopharmaceuticals. Its funds comprise over $3.3 Billion in capital raised, including venture funds focusing on company creation and private companies, and public funds focused on small and mid-cap public companies. Since 2005, over 60 Frazier Life Sciences portfolio companies, many of which were created or seeded by Frazier, have completed IPOs or M&As. Its team consists of over 40 professionals primarily located in Palo Alto, Calif. (headquarters), San Diego, Seattle, Boston, New York and London.